Isogenica uses diverse fully synthetic camelid domain antibody (VHH) libraries for internal and partnered drug discovery. Humanised synthetic libraries offer several advantages over immunisation or the use of naïve libraries, including diversity and the speed of clone isolation. During the drug discovery process, many clones might meet the desired functional properties but contain liabilities that need to be addressed before the start of the development process. Synthetic libraries include design features that reduce the number and type of liabilities thereby reducing the time of drug development. Here we show an improved library and functional data on two projects with clones generated from the llamdA library.